Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center Trial Evaluating the ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab for Advanced Melanoma

NCT07504796 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT07504796
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07504796 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center Trial Evaluating the ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab for Advanced Melanoma
Lead sponsor
NYU Langone Health
Phase
Phase 2
Overall status
Recruiting
Start date
April 13, 2026
Completion date
May 31, 2031
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced melanoma, metastatic melanoma